Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temsirolimus + vinorelbine
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Temsirolimus + vinorelbine is a combination therapy consisting of temsirolimus, an mTOR inhibitor, and vinorelbine, a vinca alkaloid chemotherapeutic agent. Temsirolimus works by blocking some of the enzymes needed for cell growth, specifically targeting the mTOR pathway. Vinorelbine disrupts microtubule assembly, preventing cell division. This combination has shown synergistic effects in clinical trials and has been studied particularly for the treatment of recurrent or refractory rhabdomyosarcoma.
02
Targets
mTOR (Mammalian target of rapamycin kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on temsirolimus + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temsirolimus + vinorelbine.